publication date: May. 4, 2018
CTEP Protocols
NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase 1 – 10187
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
National Heart Lung and Blood Institute
Childs, Richard W.
(301) 451-7128
Phase II – EA9171
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ECOG-ACRIN Cancer Research Group
Zeidan, Amer M.
(203) 737-2572
Phase II – NRG-GU006
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
NRG Oncology
Feng, Felix Yi-Chung
(415) 353-7183
Phase III – CCTG MA.39
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Canadian Cancer Trials Group
Whelan, Timothy Joseph
(905) 387-9711
Phase Other – ANBL17B5-Q
Growth Factor Receptor Trafficking and Neuroblastoma Differentiation
Children’s Oncology Group
Zage, Peter Eric
(858) 534-6494
